Viewpoint: Promise of genomics and precision medicine a ‘wave of hype without substance’

, | | March 11, 2020
b mu vwtrqwdrhjc
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

An undeclared civil war is breaking out in biomedicine. On one side is precision medicine, with its emphasis on tailoring treatments to ever-narrower groups of patients. On the other side is population health, which emphasizes predominantly preventive interventions that have broad applications across populations.

Which vision will provide the most durable and efficient path to improved health for all?

Disregarding the “breakthrough” announcements that appear on a regular basis, the question of whether precision medicine will lead to better health for all remains an open one.

We believe that genomics and precision medicine have ridden a wave of hype without substance for far too long. Unless they are able to go well beyond their thin record of empirical success and demonstrate their effectiveness in meeting the actual health needs of populations, they will be marginal players with regard to any lasting impact on the health of the public.

Related article:  What we need to know about reports suggesting CRISPR can cause cancer

Fortunately, it appears that the tide is beginning to turn toward population health, especially as a more balanced perspective of the value of polygenic risk scores — one of the most widely advocated innovations of the precision medicine movement — is beginning to emerge.

Read the original post

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend